中国上海肺癌患者诊断路径的变化
文章指出晚期非小细胞肺癌(NSCLC)伴特定基因改变(如表皮生长因子受体和微管相关蛋白样4-间变性淋巴瘤激酶)可从分子靶向治疗中显著获益,而基于程序性死亡受体1(PD-1)及其配体(PD-L1)阻断的免疫治疗可延长晚期NSCLC患者生存,尤其在PD-L1阳性表达及一线使用时。因此诊断、临床分期和分子基因分型必须快速高效。作者所在科室新患者从初次呼吸科会诊到治疗决策的中位时间为4个工作日(范围3-6),而许多国家认为14个工作日是合理时限。本文详细介绍了该科室从疑似肺癌新患者到最终治疗决策的诊断路径。
要点
- 晚期NSCLC伴EGFR或ALK基因改变者可从分子靶向治疗中显著获益。
- PD-1/PD-L1阻断免疫治疗可延长晚期NSCLC生存,尤其在PD-L1阳性及一线使用时。
- 作者科室新患者从初次呼吸科会诊到治疗决策中位4个工作日(范围3-6),许多国家合理时限为14个工作日。
核心结论
- 诊断、临床分期和分子基因分型必须快速高效,以便及时精准制定治疗策略。
研究设计与样本
- 本文描述作者所在科室疑似肺癌新患者从初次呼吸科会诊到最终治疗决策的诊断路径。
主要发现
- 作者科室新患者从初次呼吸科会诊到治疗决策的中位时间为4个工作日(范围3-6)。
- 许多国家认为14个工作日是合理时限。
临床怎么用
- 原文详细介绍了作者科室从疑似肺癌新患者到最终治疗决策的诊断路径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accumulating evidence suggest that patients with advanced non-small-cell lung cancer (NSCLC) and specific genomic alterations including epidermal growth factor receptor and microtubule-associated protein-like 4 anaplastic lymphoma kinase could significantly benefit from molecular-targeted therapies compared with chemotherapy. Recently, immunotherapy based on programmed cell death 1 (PD-1) and its ligand (PD-L1) blockade prolong survival in patients with advanced NSCLC, especially in those patients with positive expression of PD-L1 and when used in the first-line setting. Therefore, the diagnosis, clinical staging and molecular genotyping must be quick and efficient so that we can make a timely and precise decision for treatment strategy. In our department, it takes a median 4 working days (range 3-6) for a new patient from initial respiratory consultation to treatment decision, whereas in many countries, 14 workdays is considered a reasonable timeline. In this article, we will provide detailed information on the diagnostic pathway for a new patient suspected of having lung cancer to the final treatment decisions in our department.
引用
- Jiang T, Ren S, Li X, et al. The changing diagnostic pathway for lung cancer patients in Shanghai, China. Eur J Cancer. 2017. PMID: 28822887. doi:10.1016/j.ejca.2017.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。